Beijing Tong Ren Tang Chinese Medicine Company Limited
Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bjtrf · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) measures how much investors pay for each dollar of the company's trailing earnings. BJTRF's current PE ratio of 14.46x is calculated by dividing its stock price of $0.64 by its TTM earnings per share of $0.47. +37.8% elevated vs 5Y avg 10.5x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2011 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 15 fiscal years · Front-end computedMinQ1 · 25%17.8x
MedianQ3 · 75%163.4x
Max
At 14.46x, BJTRF's current P/E is lower than in 20% of its annual fiscal year readings over the past 15 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Medical - Pharmaceuticals · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Beijing Tong Ren Tang Chinese Medicine Company LimitedYou BJTRF | $536M | 14.46x | -70.0% | $0.47 |
 Allergy Therapeutics plc AGYTF | $655M | N/A | — | -$0.01 |
 Avon Technologies Plc AVNBF | $627M | 78.12x | +62.2% | $0.36 |
 Boiron S.A. BOIRF | $554M | 42.15x | -12.5% | $0.65 |
 CellaVision AB (publ) CLVSF | $322M | 24.18x | -49.8% | $6.42 |
 4DMedical Limited FDMDF | $1.6B | N/A | — | -$0.14 |
 Avisa Diagnostics Inc. FOGCF | $0M | N/A | — | -$0.14 |
Industry Average 3 peers with valid PE | — | 48.15x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 10.64x | $0.47 | +26.2% | |
2024-12-31 FY2024 | 8.43x | $0.60 | +265.3% | |
2023-12-31 FY2023 | 2.31x | $5.04 | -84.7% | |
2022-12-31 FY2022 | 15.10x | $0.77 | -5.6% | |
2021-12-31 FY2021 | 16.00x | $0.73 | -10.3% | |
2020-12-31 FY2020 | 17.83x | $0.65 | +2.4% | |
2019-12-31 FY2019 | 17.41x | $0.67 | +3.5% | |
2018-12-31 FY2018 | 16.82x | $0.69 | -15.6% | |
2017-12-31 FY2017 | 19.92x | $0.58 | -13.4% | |
2016-12-31 FY2016 | 23.00x | $0.50 | -15.6% |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Beijing Tong Ren Tang Chinese Medicine Company Limited (BJTRF) measures how much investors pay for each dollar of the company's trailing earnings. BJTRF's current PE ratio of 14.46x is calculated by dividing its stock price of $0.64 by its TTM earnings per share of $0.47.
Frequently asked questions
BJTRF pe ratio · 6 questionsBJTRF's current PE ratio is 14.46x as of 2026-06-09, based on a stock price of $0.64 and TTM EPS of $0.47. Data sourced from Financial Modeling Prep via BJTRF's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Beijing Tong Ren Tang Chinese Medicine Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09